Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003)
Study Number: MK-7684A-003
Study Summary:
The primary hypotheses are that coformulated pembrolizumab/vibostolimab is superior to pembrolizumab alone with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by blinded independent central review (BICR), and with respect to overall survival (OS), in participants with non-small cell lung cancer.
Status: Open
Open in Peoria Only
Study Coordinator(s)
- Navigator Ashton, 309-243-3611 atodd@illinoiscancercare.com
- Jessica, 309-243-3615, jjones@illinoiscancercare.com
- Amanda , 309-243-3663, amullery@illinoiscancercare.com